TerminatedNot Applicable

iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

Stopped: Business Decision

Brazil6 participantsStarted 2018-02-27

Plain-language summary

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with primary open angle glaucoma (POAG) * Subject on two ocular hypotensive medications Exclusion Criteria: * Traumatic, uveitic, neovascular, or angle closure glaucoma * Fellow eye already enrolled

What they're measuring

IOP reduction at 12 and 24 months on same number or fewer medications

Timeframe: 12 months and 24 months

Trial details

NCT IDNCT03478293

SponsorGlaukos Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-12-30

View on ClinicalTrials.gov More Primary Open Angle Glaucoma (POAG) trials